1
|
Swenson TL, Ehsanian R, Tran RT, Petersen TR, Kennedy DJ, Roche M, Oppezzo M, Noordsy DL, Fredericson M. The Association Between Well-Being and Empathy in Medical Residents: A Cross-Sectional Survey. J Integr Complement Med 2024. [PMID: 38416862 DOI: 10.1089/jicm.2023.0116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/01/2024]
Abstract
Objective: To evaluate the extent to which personal well-being may be associated with empathy, while controlling for potential confounders. Settings/Location: Residency programs throughout the United States. Subjects: A total of 407 medical residents from residencies including general medicine, surgery, specialized and diagnostic medicine participated in this study. Outcome Measures: Well-being was measured using the modified existential well-being subscale of the spiritual well-being scale. Empathy was measured using the Jefferson Scale of Empathy. Results: Well-being was found to be positively correlated with empathy when adjusted for possible confounders (p < 0.001). In addition to well-being, other factors noted to be statistically significant contributors to higher empathy scores while controlling for the others included age, gender, year in residency, specialty, and work-hours (p < 0.05 for each). After controlling for these factors, a resident's year in residency was not found to be a statistically significant contributor to empathy score. Conclusions: In this study, well-being was associated with empathy in medical and surgical residents. Empathy is a fundamental component of physician competency, and its development is an essential aspect of medical training. These findings suggest that efforts to increase well-being may promote empathy among medical residents.
Collapse
Affiliation(s)
- Theodora L Swenson
- Department of Physical Medicine and Rehabilitation, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Reza Ehsanian
- Department of Anesthesiology and Critical Care Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA
| | - Richard T Tran
- University of Colorado School of Medicine, Aurora, CO, USA
| | - Timothy R Petersen
- Department of Anesthesiology and Critical Care Medicine, Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, NM, USA
| | - David J Kennedy
- Department of Physical Medicine and Rehabilitation, Vanderbilt University School of Medicine, Nashville, TN, USA
| | - Megan Roche
- Stanford University School of Medicine, Stanford, CA, USA
| | - Marily Oppezzo
- Division of Medicine, Stanford University School of Medicine, Stanford, CA, USA
| | - Douglas L Noordsy
- Division of Psychiatry, Stanford University School of Medicine, Stanford, CA, USA
| | - Michael Fredericson
- Division of Physical Medicine and Rehabilitation, Department of Orthopaedic Surgery, Stanford University School of Medicine, Stanford, CA, USA
| |
Collapse
|
2
|
Chawla V, Bansal N, Spelber D, Desai A, Frehlich L, Ballon JS, Kalinowski A, Noordsy DL. Inspire self report scale (ISRS): A feasibility study of a Novel self report scale for people with schizophrenia spectrum disorders. J Psychiatr Res 2023; 165:248-253. [PMID: 37531843 DOI: 10.1016/j.jpsychires.2023.05.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2023] [Revised: 05/08/2023] [Accepted: 05/15/2023] [Indexed: 08/04/2023]
Abstract
Clinician-rated symptom scales are the current standard for outcome measures in Schizophrenia Spectrum Disorders (SSD) research. There has been growing interest in the development of self-report measures for people with SSD to support measurement-based care and inclusive research. We developed the Inspire Self Report Scale (ISRS), which measures the current magnitude of well-being, mood symptoms, psychosis, negative symptoms and cognition using 10 questions on a Likert or Visual analogue scale (VAS). The main aim of this report was to investigate the correlation and concordance between patient self-report and clinician ratings on the ISRS during a clinical encounter. When ratings were discordant, we sought to identify whether the participant's or psychiatrist's rating was more accurate. The results indicated a moderately strong statistically significant correlation between participant and clinician ratings. There was a moderate concordance between participant and clinician ratings on the ISRS. When the results were discordant, the participant ratings were assessed to be more accurate than the clinician rating over 70% of the time. The ISRS has distinct utility compared to existing scales due to the measurement of present symptom severity, capturing multiple clinical domains, and time efficiency and ease of use. Thus, it may be useful in clinical and research settings.
Collapse
Affiliation(s)
- Vanika Chawla
- Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
| | - Nandini Bansal
- McMaster University, 90 Main St W, Hamilton, ON, L8P 1H6, Canada.
| | - David Spelber
- Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
| | - Aakash Desai
- Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
| | - Levi Frehlich
- Department of Community Health Sciences Cumming School of Medicine, University of Calgary, Canada.
| | - Jacob S Ballon
- Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
| | - Agnieszka Kalinowski
- Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
| | - Douglas L Noordsy
- Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
| |
Collapse
|
3
|
Chawla V, Brems C, Freeman H, Ravindran A, Noordsy DL. The Future of Yoga for Mental Health Care. Int J Yoga 2023; 16:38-41. [PMID: 37583539 PMCID: PMC10424272 DOI: 10.4103/ijoy.ijoy_25_23] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 03/03/2023] [Accepted: 03/06/2023] [Indexed: 08/17/2023] Open
Abstract
Yoga is an integrated holistic system originating in India that provides a path to alleviate physical, mental, and emotional suffering. Interest in the application of yoga in health care to manage and treat psychiatric conditions has grown. While research and clinical interventions using yoga show promising results for improving mental and emotional well-being, more data are needed. This perspective article summarizes the current evidence on yoga as a treatment for mental health conditions, potential mechanisms of action, future directions, and a call to action for proactive clinical and research agendas for yoga-based interventions in mental health care.
Collapse
Affiliation(s)
- Vanika Chawla
- Department of Psychiatry, Ross Memorial Hospital, Lindsay, Ontario, Canada
| | - Christiane Brems
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Heather Freeman
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA
| | - Arun Ravindran
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Douglas L. Noordsy
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA
| |
Collapse
|
4
|
Duncan LE, Shen H, Ballon JS, Hardy KV, Noordsy DL, Levinson DF. Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia. Schizophr Bull 2018; 44:1350-1361. [PMID: 29294133 PMCID: PMC6192473 DOI: 10.1093/schbul/sbx174] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
New methods in genetics research, such as linkage disequilibrium score regression (LDSR), quantify overlap in the common genetic variants that influence diverse phenotypes. It is becoming clear that genetic effects often cut across traditional diagnostic boundaries. Here, we introduce genetic correlation analysis (using LDSR) to a nongeneticist audience and report transdisciplinary discoveries about schizophrenia. This analytical study design used publically available genome wide association study (GWAS) data from approximately 1.5 million individuals. Genetic correlations between schizophrenia and 172 medical, psychiatric, personality, and metabolomic phenotypes were calculated using LDSR, as implemented in LDHub in order to identify known and new genetic correlations. Consistent with previous research, the strongest genetic correlation was with bipolar disorder. Positive genetic correlations were also found between schizophrenia and all other psychiatric phenotypes tested, the personality traits of neuroticism and openness to experience, and cigarette smoking. Novel results were found with medical phenotypes: schizophrenia was negatively genetically correlated with serum citrate, positively correlated with inflammatory bowel disease, and negatively correlated with BMI, hip, and waist circumference. The serum citrate finding provides a potential link between rare cases of schizophrenia (strongly influenced by 22q11.2 deletions) and more typical cases of schizophrenia (with polygenic influences). Overall, these genetic correlation findings match epidemiological findings, suggesting that common variant genetic effects are part of the scaffolding underlying phenotypic comorbidity. The "genetic correlation profile" is a succinct report of shared genetic effects, is easily updated with new information (eg, from future GWAS), and should become part of basic disease knowledge about schizophrenia.
Collapse
Affiliation(s)
- Laramie E Duncan
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA,To whom correspondence should be addressed; tel: 650-723-3258, fax: 650-723-4655, e-mail:
| | - Hanyang Shen
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
| | - Jacob S Ballon
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
| | - Kate V Hardy
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
| | - Douglas L Noordsy
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
| | - Douglas F Levinson
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA
| |
Collapse
|
5
|
Abstract
PURPOSE/BACKGROUND The use of clozapine, particularly in young people, is often limited by early treatment-emergent adverse effects including drowsiness and lethargy. Concerns about adverse effects, medication adherence, and the need for blood monitoring often impede the use of clozapine in this population, leading to repeated trials of less effective medications. Current clozapine dosing recommendations are based on people further in the course of their illness and thus reflect different responsiveness and sensitivities to antipsychotic medication. As such, there is a need for evidence-based guidelines for titration and dosing of clozapine among people in early psychosis. METHODS/PROCEDURES We performed a chart review of 14 people treated with clozapine within our early psychosis team. Data regarding dose titration, response, time to discontinuation, symptom severity, weight gain, and other adverse effects were gathered at clozapine initiation, 3 months, and last available visit on clozapine. FINDINGS/RESULTS People treated with slow titration within their first year of psychosis onset achieved sustained response at very low maintenance doses (mean dose = 81 mg/d, mean duration of treatment = 200 weeks) compared with slow titration with longer duration of illness (mean dose = 350 mg/d, mean duration of treatment = 68 weeks) or standard dose titration in early psychosis (mean dose = 112 mg/d, mean duration of treatment = 38 weeks). The most common adverse effects in all groups were weight gain and sedation, with the groups requiring higher mean doses reporting a broader range of adverse effects. There was no apparent difference in the clinical global impression for severity or improvement between the slow titration and standard titration groups in people with early psychosis. These observations are synthesized into a proposed treatment guideline for use of clozapine among people in early psychosis. IMPLICATIONS/CONCLUSIONS We describe development of a slow titration approach to initiating clozapine among people in early psychosis. This approach resulted in clinical response at remarkably low maintenance doses of clozapine among people within their first year of illness, but not in those with longer duration of symptoms. Slow titration also led to good tolerability and acceptance of clozapine treatment for some patients.
Collapse
|
6
|
Hardy KV, Noordsy DL, Ballon JS, McGovern MP, Salomon C, Wiltsey Stirman S. Impact of age of onset of psychosis and engagement in higher education on duration of untreated psychosis. J Ment Health 2018; 27:257-262. [DOI: 10.1080/09638237.2018.1466047] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Kate V. Hardy
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA,
| | - Douglas L. Noordsy
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA,
| | - Jacob S. Ballon
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA,
| | - Mark P. McGovern
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA,
| | - Carmela Salomon
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA,
- Department of Developmental Disability Neuropsychiatry, University of New South Wales, Sydney, Australia, and
| | - Shannon Wiltsey Stirman
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA,
- National Center for PTSD, VA Palo Alto Healthcare System, Palo Alto, CA, USA
| |
Collapse
|
7
|
Affiliation(s)
- Douglas L Noordsy
- From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, Calif
| | - Jonathan D Burgess
- From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, Calif
| | - Kate V Hardy
- From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, Calif
| | - Lynn M Yudofsky
- From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, Calif
| | - Jacob S Ballon
- From the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, Calif
| |
Collapse
|
8
|
Ho PA, Dahle DN, Noordsy DL. Why Do People With Schizophrenia Exercise? A Mixed Methods Analysis Among Community Dwelling Regular Exercisers. Front Psychiatry 2018; 9:596. [PMID: 30483166 PMCID: PMC6243105 DOI: 10.3389/fpsyt.2018.00596] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2018] [Accepted: 10/26/2018] [Indexed: 12/12/2022] Open
Abstract
Individuals with schizophrenia have reduced rates of physical activity, yet substantial proportions do engage in independent and regular exercise. Previous studies have shown improvement in symptoms and cognitive function in response to supervised exercise programs in people with schizophrenia. There is little data on motivations of individuals who exercise independently, or their chosen type, duration, or setting of exercise. This study explores motivational parameters and subjective experiences associated with sustained, independent exercise in outpatients with a diagnosis of schizophrenia or schizoaffective disorder. Participants completed a semi-structured interview and then were given a prospective survey containing visual analog scales of symptom severity and the Subjective Exercise Experiences Scales to complete immediately before and after three sessions of exercise. Results from the semi-structured interview were analyzed by modified content analysis. The most important reason for exercise was self-image, followed closely by psychological and physical health. Among psychological effects, participants reported exercise was most helpful for mood and cognitive symptoms. The prospective ratings demonstrated 10-15% average improvements in global well-being, energy, and negative, cognitive and mood symptoms, with almost no change in psychosis, after individual exercise sessions. This suggests that non-psychotic parameters are more susceptible to inter-session decay of exercise effects, which may reinforce continued exercise participation.
Collapse
Affiliation(s)
- Patrick A Ho
- Department of Psychiatry, Geisel School of Medicine Dartmouth, Hanover, NH, United States
| | - Danielle N Dahle
- Harvard Medical School, Division of Psychotic Disorders, McLean Hospital, Belmont, MA, United States
| | - Douglas L Noordsy
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford University, Stanford, CA, United States
| |
Collapse
|
9
|
Noordsy DL, Glynn SM, Sugar CA, O’Keefe CT, Marder SR. Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. J Psychiatr Res 2017; 95:299-307. [PMID: 28942217 PMCID: PMC5653420 DOI: 10.1016/j.jpsychires.2017.09.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 08/15/2017] [Accepted: 09/07/2017] [Indexed: 10/18/2022]
Abstract
This study compares the efficacy and tolerability of olanzapine versus risperidone among patients with schizophrenia who are established in outpatient psychiatric care and entering supported employment. A multicenter, randomized, double-blind trial was conducted among 107 outpatients with schizophrenia, who were cross-titrated to flexible dose risperidone or olanzapine over 2 weeks. Clinical endpoints included time to hospitalization and persistence on assigned medication. Weight, laboratory tests, psychopathology, neurologic side effects, social adjustment and role functioning were assessed at 3-6 month intervals. Data were analyzed first by randomized treatment, and then reassessed controlling for prior medication treatment. The proportion of patients on assigned medication at 18 months was 30.9% for risperidone and 37.3% for olanzapine. Mean doses were 6.4 ± 3.2 mg daily for risperidone, and 17.0 ± 5.0 mg daily for olanzapine. The groups did not differ significantly in time to medication discontinuation, first hospitalization or first employment. There were few differences in psychopathology, laboratory, or neurological assessments between groups at 18 months. Patients randomized to olanzapine gained modestly more weight. Controlling for pre-randomization medication suggested improvement in some aspects of psychopathology from switching medications; however, switching from olanzapine to risperidone was associated with more hospitalizations. Risperidone and olanzapine have similar efficacy and tolerability in patients with schizophrenia who are participating in supported employment. Randomization to olanzapine was associated with more weight gain, but randomization from olanzapine to risperidone appeared to be associated with a greater likelihood of hospitalization. Careful monitoring of metabolic effects and participation in supported employment may have contributed to minimal weight gain and metabolic effects.
Collapse
Affiliation(s)
- Douglas L. Noordsy
- Department of Psychiatry & Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA
| | - Shirley M. Glynn
- Semel Institute for Neuroscience at UCLA, Los Angeles, CA,VA Greater Los Angeles, Los Angeles, CA
| | - Catherine A. Sugar
- Semel Institute for Neuroscience at UCLA, Los Angeles, CA,Department of Biostatistics, UCLA School of Public Health, Los Angeles, CA
| | | | - Stephen R. Marder
- Semel Institute for Neuroscience at UCLA, Los Angeles, CA,VA Greater Los Angeles, Los Angeles, CA
| |
Collapse
|
10
|
Glynn SM, Marder SR, Noordsy DL, O'Keefe C, Becker DR, Drake RE, Sugar CA. An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia. Psychiatr Serv 2017; 68:271-277. [PMID: 27799019 DOI: 10.1176/appi.ps.201500171] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
OBJECTIVE Although supported employment increases job acquisition for people with serious mental illness, data on participants' job tenure have been variable. This study evaluated the effects of a standardized work skills training program (the Workplace Fundamentals Module [WPFM]) on job tenure and other work outcomes among individuals receiving individual placement and support (IPS). The effects of two atypical antipsychotic medications on side effects were also tested. The primary hypothesis tested was that participants in IPS plus WPFM would have increased job tenure compared with those enrolled in IPS only, and the secondary hypothesis was that different antipsychotic medications would yield unique side effects. METHODS A 2×2 randomized controlled trial compared work outcomes, including job tenure, of participants receiving IPS with or without WPFM for up to two years after obtaining a job. Participants were also randomly assigned to olanzapine or risperidone. Measures of work outcomes, clinical status, and medication side effects were collected. RESULTS Among 107 participants, 63% obtained at least one job. WPFM did not increase job tenure (51.53 and 41.37 total weeks worked for IPS only and IPS plus WPFM, respectively) or affect other work outcomes. Participants on olanzapine experienced increased body mass index, whereas those on risperidone lost weight, but medications did not differentially affect clinical or job outcomes. CONCLUSIONS Clinic-based skills training did not improve work outcomes accruing from IPS. Risperidone, compared with olanzapine, may reduce body mass but has no differential effect on other work or clinical outcomes.
Collapse
Affiliation(s)
- Shirley M Glynn
- Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research
| | - Stephen R Marder
- Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research
| | - Douglas L Noordsy
- Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research
| | - Christopher O'Keefe
- Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research
| | - Deborah R Becker
- Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research
| | - Robert E Drake
- Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research
| | - Catherine A Sugar
- Dr. Glynn and Dr. Marder are with the U.S. Department of Veterans Affairs (VA) Greater Los Angeles Healthcare System, Los Angeles, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles (UCLA) (e-mail: ). Dr. Noordsy is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. Mr. O'Keefe is a graduate student at Southern New Hampshire University, Manchester. Ms. Becker and Dr. Drake are with the Rockville Institute, Westat, Lebanon, New Hampshire. Dr. Sugar is with the Department of Biostatistics, Fielding School of Public Health, and with the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, UCLA. Dr. Noordsy, Mr. O'Keefe, Ms. Becker, and Dr. Drake were with the Department of Psychiatry, and Ms. Becker and Dr. Drake were also with the Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth University, Hanover, at the time of this research
| |
Collapse
|
11
|
Noordsy DL. Ethical Issues in the Care of People With Schizophrenia. Focus (Am Psychiatr Publ) 2016; 14:349-353. [PMID: 31975817 PMCID: PMC6526796 DOI: 10.1176/appi.focus.20160011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Affiliation(s)
- Douglas L Noordsy
- Douglas L. Noordsy, M.D., is with the Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA (e-mail: )
| |
Collapse
|
12
|
Green AI, Brunette MF, Dawson R, Buckley P, Wallace AE, Hafez H, Herz M, Narasimhan M, Noordsy DL, O'Keefe C, Sommi RW, Steinbook RM, Weeks M. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry 2015; 76:1359-65. [PMID: 26302441 DOI: 10.4088/jcp.13m08838] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Accepted: 08/05/2014] [Indexed: 10/23/2022]
Abstract
OBJECTIVE Alcohol use disorders worsen the course of schizophrenia. Although the atypical antipsychotic clozapine appears to decrease alcohol use in schizophrenia, risperidone does not. We have proposed that risperidone's relatively potent dopamine D2 receptor blockade may partly underlie its lack of effect on alcohol use. Since long-acting injectable (LAI) risperidone both results in lower average steady-state plasma concentrations than oral risperidone (with lower D2 receptor occupancy) and encourages adherence, it may be more likely to decrease heavy alcohol use (days per week of drinking 5 or more drinks per day) than oral risperidone. METHOD Ninety-five patients with DSM-IV-TR diagnoses of schizophrenia and alcohol use disorder were randomized to 6 months of oral or LAI risperidone between 2005 and 2008. Explanatory (efficacy) analyses were carried out to evaluate the potential benefits of LAI under suitably controlled conditions (in contrast to real-world settings), with intent-to-treat analyses being secondary. RESULTS Explanatory analyses showed that heavy drinking in the oral group worsened over time (P = .024) and that there was a statistical trend toward significance in the difference between the changes in heavy drinking days in the oral and LAI groups (P = .054). Furthermore, the 2 groups differed in the mean number of drinking days per week (P = .035). The intent-to-treat analyses showed no difference in heavy drinking but did show a difference in average drinking days per week similar to that obtained from the explanatory analyses (P = .018). Neither explanatory nor intent-to-treat analyses showed any between-group differences in alcohol use as measured by intensity or the Alcohol Use Scale. The plasma concentrations of the active metabolite 9-hydroxyrisperidone were significantly lower in patients taking LAI (P < .05), despite their significantly (overall) better treatment adherence (P < .005). CONCLUSION For the population considered here, schizophrenia patients with alcohol use disorder appear to continue drinking some alcohol while taking either form of risperidone. Nonetheless, our data suggest that injectable risperidone may be a better choice than the oral form for these dual diagnosis patients. TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT00130923.
Collapse
Affiliation(s)
- Alan I Green
- One Medical Center Drive, HB 7750, Lebanon, NH 03756
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
Substance use disorders, common in patients with schizophrenia, can lead to poor outcomes. Here we review the literature on the use of antipsychotics in patients with co-occurring schizophrenia and substance use disorder as well as evidence for the use of adjunctive pharmacological treatments targeting substance use in these patients. We also discuss a neurobiological formulation suggesting that the cooccurrence of these disorders may be related to a dysfunction in the dopamine mediated brain reward circuitry. Typical antipsychotics do not appear to decrease substance use in this population. Randomized, controlled trials provide some support for use of the atypical antipsychotic clozapine for co-occurring cannabis use disorder, naltrexone and disulfiram for alcohol use disorder, and also nicotine replacement therapy, sustained-release bupropion and varenicline for tobacco use disorder. Nonetheless, data regarding treatment in patients with these co-occurring disorders are still limited, and many studies reported to date have been either underpowered or did not include a control condition. Further research is needed to evaluate optimal pharmacotherapeutic strategies for this population.
Collapse
Affiliation(s)
- Sarah C. Akerman
- Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
| | - Mary F. Brunette
- Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
| | - Douglas L. Noordsy
- Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
| | - Alan I. Green
- Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
| |
Collapse
|
14
|
McDermott M, Noordsy DL, Traum M. Neuroleptic malignant syndrome during multiple antipsychotic therapy. Community Ment Health J 2013; 49:45-6. [PMID: 22038421 DOI: 10.1007/s10597-011-9452-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2011] [Accepted: 10/06/2011] [Indexed: 11/25/2022]
Affiliation(s)
- Margaret McDermott
- Psychopharmacology Research Group, Dartmouth Medical School, Lebanon, NH 03756, USA.
| | | | | |
Collapse
|
15
|
Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. J Dual Diagn 2011; 7:50-63. [PMID: 25914610 PMCID: PMC4407140 DOI: 10.1080/15504263.2011.570118] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVE Cannabis use disorder is the most common co-occurring drug use disorder in people with schizophrenia and is associated with poor outcomes. We launched a randomized controlled trial to assess the impact of clozapine compared with treatment as usual on cannabis use in patients with schizophrenia and co-occurring cannabis use disorder. METHODS Thirty-one patients with schizophrenia and co-occurring cannabis use disorder were randomly assigned to switch to clozapine or to stay on their current antipsychotic and were then followed weekly for 12 weeks. Blinded raters assessed participants weekly with the Timeline Follow-back for substance use and the expanded Brief Psychiatric Rating Scale for symptoms. Longitudinal random effects models were used to investigate the time-varying differences in cannabis use and other outcomes between the treatment as usual and clozapine groups. RESULTS The two groups differed in average intensity of cannabis use by approximately 4.5 joints/week, with lesser use in the clozapine group (t = -1.77; df = 28.5; p=.086; effect size ~ 0.6). Symptoms and functioning were not different between the two groups. CONCLUSIONS Clozapine may reduce cannabis use among patients with schizophrenia and co-occurring cannabis use disorder. Further controlled trials are warranted.
Collapse
Affiliation(s)
- Mary F Brunette
- Department of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire 03755
| | - Ree Dawson
- Frontier Science Research and Technology, Boston, MA
| | | | - Meera Narasimhan
- Department of Psychiatry, University of South Carolina, Columbia, SC
| | - Douglas L Noordsy
- Department of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire 03755
| | - Joanne Wojcik
- Department of Psychiatry, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
| | - Alan I Green
- Department of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire 03755
| |
Collapse
|
16
|
Noordsy DL, Phillips GA, Ball DE, Linde-Zwirble WT. Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia. Patient Prefer Adherence 2010; 4:263-71. [PMID: 20694186 PMCID: PMC2915559 DOI: 10.2147/ppa.s6053] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2010] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE To evaluate health care resource utilization in patients with schizophrenia who continued newly prescribed antipsychotic medications, compared with those switching to different treatments. METHODS Adults with schizophrenia in the California Medicaid (MediCal) database who initiated treatment with index medications in 1998-2001, were classified as having: 1) abandoned antipsychotic medications; 2) switched to another medication; or 3) continued with the index antipsychotic, for up to 6 months after the index date. RESULTS Of 2300 patients meeting eligibility criteria, 1382 (60.1%) continued index medications, 480 (20.9%) switched, and 438 (19.0%) abandoned antipsychotic treatment. Utilization in several resource categories occurred significantly more frequently among patients whose regimens were switched (vs those continuing index medications). These included using psychiatric (24.2% vs 14.5%; P < 0.001) or nonpsychiatric (31.5% vs 24.3%; P < 0.05) emergency services; being admitted to a hospital (10.6% vs 7.4%; P < 0.05); making nonpsychiatric outpatient hospital visits (43.3% vs 36.4%; P < 0.05) or nonpsychiatric physician visits (62.7% vs 56.4%; P < 0.05); and using other outpatient psychiatric (53.3% vs 40.7%; P < 0.001) or nonpsychiatric (82.7% vs 74.6%; P < 0.001) services. CONCLUSIONS Switching antipsychotic medications is associated with significantly increased health care resource utilization (vs continuing treatment).
Collapse
Affiliation(s)
- Douglas L Noordsy
- Department of Psychiatry, Dartmouth Medical School, Lebanon, NH, USA
- Correspondence: Douglas L. Noordsy, Department of Psychiatry, Dartmouth Medical School, 1 Medical Center Drive, Lebanon, NH 03756, USA, Tel +1 603 650 5805, Fax +1 603 650 7820, Email
| | - Glenn A Phillips
- Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
| | - Daniel E Ball
- Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA
| | | |
Collapse
|
17
|
|
18
|
Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 2007; 34:61-71. [PMID: 17574793 PMCID: PMC2930488 DOI: 10.1016/j.jsat.2007.01.008] [Citation(s) in RCA: 91] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2006] [Revised: 01/08/2007] [Accepted: 01/20/2007] [Indexed: 11/20/2022]
Abstract
Substance use disorder is common in patients with schizophrenia and dramatically worsens their outcome. The typical antipsychotic medications, introduced more than 50 years ago, are effective for the treatment of psychosis but may have only limited efficacy in patients with these co-occurring disorders because patients continue to use substances while taking them. In preliminary studies, however, several of the atypical antipsychotic medications have shown promise for reducing alcohol and drug use in patients with schizophrenia. A neurobiological formulation is discussed, suggesting that the use of substances in patients with schizophrenia may be based on a dysfunction within the dopamine-mediated brain reward circuitry and that clozapine, in particular, may potentially ameliorate this dysfunction and lessen the desire for substance use. Medications for the treatment of alcohol use disorders, such as disulfiram, naltrexone, and acamprosate, as well as other adjunctive medications, may also be useful. Further studies are required to establish a solid evidence base of best practices for the use of medications in these patients.
Collapse
Affiliation(s)
- Alan I Green
- Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03756, USA.
| | | | | | | |
Collapse
|
19
|
Affiliation(s)
- Alan I Green
- Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA
| | | | | | | |
Collapse
|
20
|
Mueser KT, Noordsy DL, Drake RE, Fox L. Troubles mentaux graves et abus de substances : composantes efficaces de progammes de traitements intégrés à l’intention des personnes présentant une comorbidité. SMQ 2007. [DOI: 10.7202/014524ar] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Résumé
Les approches traditionnelles de soins pour patients souffrant de problèmes de comorbidité qui étaient fondées sur des traitements séquentiels ou en parallèle ont échoué dans les cas de santé mentale et d'abus de substance, ce qui a conduit au développement de programmes de traitements intégrés. Dans cet article, les auteurs définissent les traitements intégrés destinés aux patients ayant ce double diagnostic et identifient les composantes clés des programmes intégrés efficaces, y compris la pratique outreach, l'approche holistique, le partage de la prise de décision, la réduction des méfaits, l'engagement à long terme et le traitement par étapes (basé sur l'approche motivationnelle). Le concept d'étapes de traitement est décrit afin d'illustrer les différents stades de motivation vécus par les personnes à mesure qu'elles se rétablissent de leur dépendance aux substances : l'engagement, la persuasion, le traitement actif et la prévention des rechutes. Les étapes de traitement servent à guider les cliniciens dans l'identification d'objectifs de traitement appropriés à l'état de motivation des patients, et à choisir des interventions fondées sur ces objectifs. En reconnaissant le stade de traitement de chaque personne, les cliniciens peuvent optimiser les résultats en choisissant des interventions qui sont appropriées à l'état de motivation de la personne ou à l'étape de traitement et ainsi minimiser les abandons. Ces programmes intégrés diffèrent dans les services spécifiques qu'ils dispensent. Toutefois, ils partagent des éléments communs dans leur philosophie et leurs valeurs. Des recherches documentent les effets bénéfiques de ces programmes qui s'avèrent de bon augure pour le pronostic à long terme des personnes présentant une comorbidité.
Collapse
|
21
|
Kinon BJ, Noordsy DL, Liu-Seifert H, Gulliver AH, Ascher-Svanum H, Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006; 26:453-61. [PMID: 16974184 DOI: 10.1097/01.jcp.0000236658.16286.25] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
This study compared the effects of olanzapine (OLZ) with those of quetiapine (QUE) for improving negative symptoms in patients diagnosed with schizophrenia or schizoaffective disorder who had prominent negative symptoms and marked deficits in social or occupational functioning. In this 6-month, multicenter, double-blind clinical trial, patients were randomized to treatment with OLZ (n = 171, 10-20 mg/d) or QUE (n = 175, 300-700 mg/d). Patients were treated at community mental health centers and assigned case managers who developed individualized psychosocial treatment plans. The primary efficacy measure was the reduction in negative symptoms using the Scale for the Assessment of Negative Symptoms. Secondary measures assessed changes in functioning, psychopathology, and treatment tolerability. Treatment with OLZ or QUE led to a significant reduction in negative symptoms, with no between-group difference (P = 0.09). Both treatment groups also showed significant improvement on most efficacy measures. Olanzapine-treated patients showed significantly greater improvement on positive symptoms and on several measures of functioning including Global Assessment of Functioning Scale, Quality of Life Instrumental Role domain, and level of effort in psychosocial or occupational rehabilitation programs. Significantly more OLZ-treated patients completed the study (52.6% OLZ, 37.7% QUE, P = 0.007). Treatment differences in safety were relatively small and not thought to be clinically relevant. Patients with schizophrenia who manifest prominent negative symptoms and marked functional deficits demonstrated significant improvement in negative symptoms after treatment with OLZ or QUE. Greater improvement in positive symptoms and a greater study completion rate may hold relevance to enhanced functional outcomes observed after OLZ therapy.
Collapse
Affiliation(s)
- Bruce J Kinon
- Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
| | | | | | | | | | | |
Collapse
|
22
|
|
23
|
Abstract
Research on the optimal pharmacotherapy for people with schizophrenia and co-occurring substance use disorders remains in its infancy. This report reviews existing data and provides an update on recent research. The confluence of findings is consistent with a model of a reward dysfunction inherent in the neuropathology of schizophrenia, leading to a heightened vulnerability of people with schizophrenia to substance use disorders. Studies indicate that patients with dual disorders have difficulty tolerating conventional antipsychotics, have higher rates of medication nonadherence, and have greater impulsivity and sensation seeking. Limited evidence suggests that clozapine treatment may be associated with reduced substance abuse, with weaker evidence suggesting that other novel antipsychotics may have similar, but potentially less potent, effects. Controlled trials to test the effects of these medications are underway. A number of recent studies indicate that bupropion can facilitate reduced tobacco smoking among patients with schizophrenia. The preferential use of novel antipsychotics, a lower threshold for prescription of clozapine, the use of bupropion for smoking cessation, careful monitoring of compliance, and possible use of other medications for substance use disorders when indicated are recommended in pharmacologic management for people with co-occurring substance use disorders and schizophrenia.
Collapse
Affiliation(s)
- Douglas L Noordsy
- Department of Psychiatry, Dartmouth Medical School, One Medical Center Drive, Lebanon, NH 03756, USA
| | | |
Collapse
|
24
|
Abstract
OBJECTIVES Because use of benzodiazepines may exacerbate existing substance use disorders or become abused substances, prescription of benzodiazepines for patients with severe mental illness (schizophrenia or bipolar disorder) and co-occurring substance use disorders (abuse or dependence) is controversial. The authors examined benzodiazepine use and associated psychiatric, substance abuse, and institutional outcomes in a six-year longitudinal study of patients with co-occurring disorders. METHODS At baseline and yearly follow-up for six years, 203 patients with co-occurring severe mental illness and substance use disorder were prospectively assessed for medication use, substance use, psychiatric symptoms, use of hospitalization, and quality of life. RESULTS Almost one-half of the patients (43 percent) reported taking prescribed benzodiazepines at the time of at least one assessment. Patients taking prescribed benzodiazepines were more likely to have high scores on measures of overall symptoms and affective symptoms (anxiety and depression) and low ratings for general quality of life throughout the study. Benzodiazepine use was unrelated to remission of substance use disorder or hospitalization, but a greater proportion of patients who were prescribed benzodiazepines developed benzodiazepine abuse, compared with those who were not prescribed benzodiazepines (15 percent compared with 6 percent). CONCLUSIONS Prescription benzodiazepine use was common among patients with co-occurring severe mental illness and a substance use disorder and was not associated with any of the measured outcomes other than increasing the likelihood of benzodiazepine abuse. Physicians should consider other treatments for anxiety in this population.
Collapse
Affiliation(s)
- Mary F Brunette
- Department of Psychiatry, Dartmouth Medical School, Concord, New Hampshire 03301, USA.
| | | | | | | |
Collapse
|
25
|
Abstract
BACKGROUND Given growing concern about weight gain associated with treatment with antipsychotic agents, we performed a retrospective chart review of patients who reversed weight gain associated with antipsychotic treatment to determine the prevalence of reversal and both the course and methods used. METHOD Prevalence of weight gain reversal was determined by surveying clinicians. Of 53 patients who gained >/= 20 lb (9 kg) during antipsychotic treatment, an initial sample of 12 patients (23%) who subsequently lost >/= 10 lb (5 kg) was identified. These 12 patients were combined with additional patients, identified by the authors, who met the same criteria for reversal of antipsychotic-associated weight gain to form a total sample of 35 patients. Course and methods of weight loss were determined by reviewing these patients' charts. Information about interventions and both antipsychotic and other medications was collected. RESULTS At the point of maximum weight gain, the total sample of 35 patients had gained a mean of 29.36 kg (64.73 lb) over a mean of 33 months. At the point of greatest weight loss (56 months), these patients were a mean of 10.86 kg (23.94 lb) over their baseline weight. The most recent weight for patients (63 months) indicated they were 14.81 kg (32.65 lb) over baseline. The most frequent weight loss interventions were regular dietician visits (42.9% [N = 15]), self-directed diet (28.6% [N = 10]), and weight loss as a treatment goal (25.7% [N = 9]). The least frequent interventions were no intervention (5.7% [N = 2]), psychiatrist addressing weight loss (5.7% [N = 2]), and surgery (2.9% [N = 1]). No significant change in medications prescribed was found. CONCLUSION Some patients who gain weight while taking antipsychotic medications are able to stop gaining and lose weight over time, largely through behavioral interventions. While patients' weight fluctuated, this group sustained a loss of approximately half their initial gain. Dietary interventions appear promising and should be explored further to prevent and reverse weight gain.
Collapse
|
26
|
|
27
|
Mueser KT, Noordsy DL, Fox L, Wolfe R. Disulfiram treatment for alcoholism in severe mental illness. Am J Addict 2003; 12:242-52. [PMID: 12851020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/03/2023] Open
Abstract
Controlled research has shown that supervised disulfiram is an effective treatment for alcoholism. Despite this, little is known about the effects of disulfiram in persons with alcoholism and severe mental illness. We conducted comprehensive chart reviews on 33 patients with alcoholism and severe mental illness (70% schizophrenia or schizoaffective disorder) who had been prescribed disulfiram. Twenty-one percent reported side effects from disulfiram, whereas significant psychiatric complications were not reported. Although 76% of patients reported drinking while on disulfiram, only 28% experienced negative reactions to alcohol. Sixty-four percent of the patients saw a remission of alcoholism for at least one year during a three-year follow-up, and 30% experienced a two-year remission. Disulfiram treatment was associated with decreases in days hospitalized but not with changes in work status. The results suggest disulfiram may be a useful adjunctive treatment for alcoholism in patients with severe mental illness and that controlled research is needed to evaluate its effects in this population.
Collapse
Affiliation(s)
- Kim T Mueser
- Department of Psychiatry, Dartmouth Medical School, Concord, NH, USA.
| | | | | | | |
Collapse
|
28
|
|
29
|
Abstract
OBJECTIVE This study evaluated the outcomes of patients in a community mental health center who switched from treatment with another antipsychotic to olanzapine treatment. It also sought to determine whether simultaneous access to case management and psychosocial rehabilitation and olanzapine leads to enhanced functional improvement. METHODS Six-month outcomes for a consecutive series of 104 patients who switched from a conventional antipsychotic medication to olanzapine were evaluated. Forty-nine patients in the same treatment program who continued to take conventional antipsychotics were also monitored as a reference group. Outcomes of the group receiving olanzapine were compared with their own baseline status and with outcomes of the reference group. RESULTS At six months, patients in the olanzapine group demonstrated significant improvement over baseline across multiple measures of symptoms and psychosocial function. Compared with the reference group, the olanzapine group was more symptomatic at baseline and demonstrated significantly greater improvement at follow-up on the Brief Psychiatric Rating Scale and all subscales; Mini Psychiatric Rating Scale negative symptom, disorganization, anxiety, depression, and medication side effects items; and Clinical Global Improvement scale and Case Manager's Rating Scale-Plus illness factors. There was a trend toward superior improvement in psychosocial functioning among patients in the olanzapine group that achieved significance when patients in acute relapse at baseline were excluded. CONCLUSIONS Olanzapine is effective in managing markedly to severely ill patients with psychotic disorders in a community mental health center. Simultaneous treatment with olanzapine, case management, and psychosocial rehabilitation leads to enhanced functional improvement among nonrelapsing patients.
Collapse
Affiliation(s)
- D L Noordsy
- Mental Health Center of Greater Manchester, New Hampshire, USA.
| | | | | | | |
Collapse
|
30
|
Mueser KT, Noordsy DL, Drake RE, Fox L. [Integrated treatment for severe mental illness and substance abuse: Effective components of programs for persons with co-occurring disorders.]. Sante Ment Que 2001; 26:22-46. [PMID: 18253604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Traditional approaches to treating clients with co-occurring disorders based sequential or parallel mental health and substance abuse treatments have failed, leading to the development of integrated treatment programs. In this article we define integrated treatment for clients with co-occurring disorders, and identify the core components of effective integrated programs, including: assertive outreach, comprehensiveness, shared decision-making, harm-reduction, long-term commitment, and stage-wise (motivation-based) treatment. The concept of stages of treatment is described to illustrate the different motivational states through which clients progress as they recover from substance abuse: engagement, persuasion, active treatment, and relapse prevention. The stages of treatment have clinical utility for guiding clinicians in identifying appropriate treatment goals matched to clients' motivational states, and selecting interventions based on these goals. By recognizing each client's current stage of treatment, clinicians can optimize outcomes by selecting interventions that are appropriate to the client's current motivational state or stage of treatment, and minimize clients dropping out from treatment. Effective integrated treatment programs for clients with co-occurring disorders differ in the specific services they provide, but share common elements in their philosophy and values. Research documents the beneficial effects of these programs, which bodes well for the long-term prognosis of clients with co-occurring disorders.
Collapse
|
31
|
Noordsy DL, Torrey WC, Mead S, Brunette M, Potenza D, Copeland ME. Recovery-oriented psychopharmacology: redefining the goals of antipsychotic treatment. J Clin Psychiatry 2000; 61 Suppl 3:22-9. [PMID: 10724130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
Abstract
The traditional goals of psychopharmacology stem from the medical model. Rehabilitation interventions attempt to improve aspects of functioning in patients with chronic illnesses that are not responsive to biological intervention. Recovery is a concept emanating from the consumer self-help movement. It describes a move away from the patient role defined by a diagnostic label toward community membership defined by relationships and responsibilities in the community. Comprehensive care for people with psychotic disorders can include attention to each realm. This article provides an overview of the 3 models of care and describes a role for the psychopharmacologist in each as well as his or her unique potential to incorporate all 3. We outline potential synergistic benefits of integrating recovery-, rehabilitation-, and medical-model thinking into the practice of psychopharmacology and explore implications for the goals and outcomes of treatment for people with psychotic disorders.
Collapse
Affiliation(s)
- D L Noordsy
- Department of Psychiatry, Dartmouth Medical School, Hanover, NH, USA.
| | | | | | | | | | | |
Collapse
|
32
|
Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999; 60 Suppl 19:47-51; discussion 52-3. [PMID: 10507280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
This article presents a consecutive case series of 70 patients treated with olanzapine, case management, and psychosocial rehabilitation in a community mental health setting. This group demonstrated highly significant improvement on all analyzed measures of symptoms and psychosocial function at 6-month follow-up. These findings suggest that results of efficacy studies of olanzapine will generalize to the community mental health setting. Furthermore, prescribing olanzapine in combination with case management and rehabilitation yields positive functional outcomes.
Collapse
Affiliation(s)
- D L Noordsy
- The Mental Health Center of Greater Manchester and Dartmouth Medical School, New Hampshire 03101, USA
| | | |
Collapse
|
33
|
Mueser KT, Drake RE, Ackerson TH, Alterman AI, Miles KM, Noordsy DL. Antisocial personality disorder, conduct disorder, and substance abuse in schizophrenia. J Abnorm Psychol 1997; 106:473-7. [PMID: 9241949 DOI: 10.1037/0021-843x.106.3.473] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The validity of subtypes based on antisocial personality disorder (APD) or childhood conduct disorder without adult APD (CD only) in patients with schizophrenia (or schizoaffective disorder) and a substance use disorder (abuse or dependence) was examined. APD patients scored lower on personality measures related to socialization and higher on antisocial behavior, psychopathy, and aggression. APD patients also reported higher rates of aggression and legal problems. APD, and to a lesser extent CD only, was associated with more severe psychiatric symptoms, an earlier age of onset of substance abuse, more severe symptoms of substance abuse, and a stronger family history of substance abuse and psychiatric hospitalization. The findings suggest that schizophrenia patients with APD represent a high-risk subgroup vulnerable to more severe substance abuse, psychiatric impairment, aggression, and legal problems.
Collapse
Affiliation(s)
- K T Mueser
- New Hampshire-Dartmouth Psychiatric Research Center, Concord 03301, USA.
| | | | | | | | | | | |
Collapse
|
34
|
Noordsy DL, Schwab B, Fox L, Drake RE. The role of self-help programs in the rehabilitation of persons with severe mental illness and substance use disorders. Community Ment Health J 1996; 32:71-81; discussion 83-6. [PMID: 8635319 DOI: 10.1007/bf02249369] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Substance abuse treatment programs in the United States frequently incorporate self-help approaches, but little is known about the use of self-help groups by individuals with dual disorders. This paper brings together several current studies on the role of self-help programs in treating substance use disorders among individuals with severe mental illness. These studies indicate that only a minority of individuals with dual disorders become closely linked to self-help. Psychiatric diagnosis and possibly social skills are correlates of participation. Dually disorders consumers often experience the use of 12-step philosophy and jargon by mental health professionals as alienating and unempathic. The authors propose suggestions for incorporating self-help approaches into the comprehensive community care of individuals with dual disorders.
Collapse
Affiliation(s)
- D L Noordsy
- NH-Dartmouth Psychiatric Research Center, Lebanon 03766, USA
| | | | | | | |
Collapse
|
35
|
Abstract
Group treatment is a widely practiced intervention for persons with dual diagnoses. This chapter reviews the rationale for group treatment and discusses four different approaches to group intervention: twelve-step, educational-supportive, social skills, and stagewise treatment.
Collapse
|
36
|
Affiliation(s)
- R E Drake
- West Central Services, Inc., Lebanon, NH 03766, USA
| | | |
Collapse
|
37
|
Abstract
Previous research has shown that family history of alcoholism (FHA) is associated with several aspects of the development and expression of alcohol use disorder in people who are not mentally ill. This study examined FHA in a group of 66 schizophrenic outpatients who were well characterized in terms of their alcohol use and were followed prospectively in treatment for 4 years. The FHA-positive probands (42.4% of the group) were more likely to have alcohol use disorder. Contrary to our prediction, the relationship between FHA and alcoholism in the probands was significant for women but not for men. Among schizophrenic probands with alcoholism, positive FHA was associated with more severe alcoholism and with the use of other drugs. Probands with positive FHA also responded less well to alcoholism treatment than did probands with negative FHA. These exploratory findings have significant implications for understanding risk, for conducting assessment, and for studying treatment, but should be confirmed in larger and more representative samples of people with schizophrenia.
Collapse
Affiliation(s)
- D L Noordsy
- New Hampshire-Dartmouth Psychiatric Research Center, Concord 03301
| | | | | | | |
Collapse
|
38
|
|
39
|
Osher FC, Drake RE, Noordsy DL, Teague GB, Hurlbut SC, Biesanz JC, Beaudett MS. Correlates and outcomes of alcohol use disorder among rural outpatients with schizophrenia. J Clin Psychiatry 1994; 55:109-13. [PMID: 8071247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND The use of alcohol by persons with schizophrenia is common and has been associated with increased severity of psychiatric symptoms, multiple psychosocial problems, abuse of other drugs, and poor treatment outcomes. Most of the previous research in this area has been with urban patients. METHOD The authors examined the correlates and outcomes of alcohol use in a rural sample of 75 DSM-III-R outpatients with schizophrenia. Based on multiple measures, 25% (N = 19) of 75 rural patients with schizophrenia were diagnosed with current co-occurring alcohol use disorders. Clinicians' ratings and self-reported symptoms were used to examine correlates of alcohol use, and the study group was followed prospectively for 1 year to identify all episodes of rehospitalization, incarceration, or literal homelessness. RESULTS Alcohol use disorder was statistically significantly associated with unstable housing, conceptual disorganization, denial of mental illness, and rehospitalization during 1-year follow-up. Several trends suggested that alcohol use was also related to positive symptoms of psychosis. CONCLUSION Among rural patients with schizophrenia, alcohol use appears to play a significant role in destabilizing psychosocial adjustment. These results replicate similar findings in urban settings.
Collapse
Affiliation(s)
- F C Osher
- Division of Demonstration Programs, Center for Mental Health Services, Rockville, MD 20857
| | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
Substance abuse is the most common comorbid complication of severe mental illness. Current clinical research converges on several emerging principles of treatment that address the scope, pace, intensity, and structure of dual-diagnosis programs. They include a) assertive outreach to facilitate engagement and participation in substance abuse treatment, b) close monitoring to provide structure and social reinforcement, c) integrating substance abuse and mental health interventions in the same program, d) comprehensive, broad-based services to address other problems of adjustment, e) safe and protective living environments, f) flexibility of clinicians and programs, g) stage-wise treatment to ensure the appropriate timing of interventions, h) a longitudinal perspective that is congruent with the chronicity of dual disorders, and i) optimism.
Collapse
Affiliation(s)
- R E Drake
- New Hampshire-Dartmouth Psychiatric Research Center, Concord 03301
| | | | | | | | | |
Collapse
|
41
|
Abstract
Utilization and cost of institutional and outpatient services were prospectively measured over 1 year for three groups of schizophrenic patients: current substance abusers, past substance abusers, and those without a history of substance abuse. Current abusers had significantly greater utilization and cost of institutional (hospital and jail) services. Current abusers also had greater utilization of emergency services. There were no significant differences between the groups in utilization and cost of other services, including psychosocial rehabilitation, outpatient treatment (case management, psychotherapy, and psychiatric visits), and housing supports. The implications for developing cost-effective treatments for dually diagnosed individuals are discussed.
Collapse
Affiliation(s)
- S J Bartels
- West Central Services, Lebanon, New Hampshire 03766
| | | | | | | | | | | |
Collapse
|
42
|
Abstract
In this pilot study, the authors assessed 4-year outcomes for 18 schizophrenic outpatients with alcoholism who were treated in an innovative dual-diagnosis program. Over half (61.1%) achieved stable remissions from alcoholism. The mean duration of remission was 26.5 months.
Collapse
Affiliation(s)
- R E Drake
- New Hampshire-Dartmouth Psychiatric Research Center, Concord 03301
| | | | | |
Collapse
|
43
|
|
44
|
Abstract
Comorbid alcohol use disorders are common in schizophrenia. Although a variety of explanatory hypotheses involving self-medication have been proposed, few data available regarding schizophrenic patients' subjective experiences while using alcohol. We report interview data from 75 DSM-III-R schizophrenic outpatients regarding their subjective responses to alcohol. Over half of our sample reported that alcohol improved social anxiety, tension, dysphoria, apathy, anhedonia, and sleep difficulties. Other nonpsychotic experiences were frequently improved as well. In contrast, no more than 15% of subjects reported that alcohol relieved any specific psychotic symptom; similar proportions of subjects reported that alcohol aggravated psychotic symptoms. Reporting that alcohol had a positive effect on nonpsychotic experiences was associated with having lifetime alcohol use disorders. Reporting that alcohol relieved psychotic symptoms was associated both with having lifetime alcohol use disorders and with the number of psychotic symptoms reported. We discuss the implications of these findings for understanding alcohol abuse and dependence among schizophrenics.
Collapse
Affiliation(s)
- D L Noordsy
- Department of Psychiatry, Dartmouth Medical School, Hanover, New Hampshire
| | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
New Hampshire's specialized dual diagnosis services include continuous treatment teams and substance abuse treatment groups within each mental health center. These services are embedded in an extensive system of care for the dually diagnosed.
Collapse
Affiliation(s)
- R E Drake
- New Hampshire-Dartmouth Psychiatric Research Center
| | | | | | | | | |
Collapse
|
46
|
Abstract
Alcohol use disorders are common comorbid conditions in schizophrenia, and their presence is associated with poor adjustment and poor treatment response. Standard alcohol assessment instruments have not been validated for use with schizophrenic patients, and several authors have questioned the validity of these patients' self-reports. A reliable and valid screening procedure for assessing alcohol use is needed. The present study used the following three methods to evaluate a rural sample of 75 outpatients with DSM-III-R schizophrenia or schizoaffective disorder: (1) clinical records; (2) research interviews using standard alcohol assessment instruments; and (3) case managers' ratings. In addition, consensus diagnoses, determined by combining information from all three methods with intensive case reviews, were used to determine the sensitivity and specificity of the other approaches. As expected, clinical evaluations frequently missed alcohol problems. Research interviews and case managers' ratings differentiated between alcoholic and nonalcoholic schizophrenic patients and were highly correlated. Case managers' ratings, which incorporated longitudinal observations of behavior and collateral reports as well as interview data, were more sensitive measures of current alcohol use disorders than research interviews. Subjects frequently manifested alcohol-related problems that interfered with community adjustment without the full dependence syndrome, suggesting that schizophrenic patients may be particularly vulnerable to negative effects of alcohol.
Collapse
Affiliation(s)
- R E Drake
- West Central Services, Lebanon, NH 03766
| | | | | | | | | | | |
Collapse
|
47
|
Ravaris CL, Sateia MJ, Beroza KW, Noordsy DL, Brinck-Johnsen T. Effect of ketoconazole on a hypophysectomized, hypercortisolemic, psychotically depressed woman. Arch Gen Psychiatry 1988; 45:966-7. [PMID: 3262333 DOI: 10.1001/archpsyc.1988.01800340094019] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|